PD-L1 Expression in Extracellular Vesicles as a Predictive Biomarker
Extracellular vesicles carrying PD-L1 as cargo may function as a predictive biomarker for immunotherapy response in NSCLC.
Extracellular vesicles carrying PD-L1 as cargo may function as a predictive biomarker for immunotherapy response in NSCLC.
At 2 years, twice as many patients with stage II to IIIA disease in the osimertinib group were alive and disease-free as in the placebo group.
This analysis compared the efficacy outcomes of subgroups of patients with NSCLC treated with alectinib vs crizotinib according to ALK tumor status.
Sometimes the distinctions between cancer treatment groups are a little blurry. Here’s a guide to their definitions and origins.
Neoadjuvant treatment with chemotherapy plus nivolumab resulted in a greater frequency of NSCLC downstaging compared with chemotherapy or ICI treatment alone.
Bemcentinib, an AXL inhibitor, was tolerable and demonstrated antitumor activity in combination with pembrolizumab in AXL-positive, relapsed NSCLC.
Telemedicine has become more crucial than ever in the continuing wake of the COVID-19 pandemic. Research from the US Centers for Disease Control and Prevention (CDC) showed that there was a 50% increase utilization of telehealth services in the first quarter of 2020 compared with 2019, and a 154% increase in week 13 of 2020…
Pediatric mesothelioma demonstrated distinct characteristics from adult disease, including good prognosis.
The survival-inferred fragility index of phase 3 trials for immune checkpoint inhibitors suggests that, despite statistical significance, survival data do not show a robust clinical benefit.
The FDA approved FoundationOne CDx as a companion diagnostic for treatment selection of alpelisib for breast cancer, rucaparib for some gynecologic cancers, and alectinib for lung cancer.